

Barcelona, 12th December 2023

OTHER RELEVANT INFORMATION

Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology

In accordance with Securities Markets Law, Almirall S.A. (“Almirall”) announces the following:

A multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.

- The multi-target research and development partnership will focus on severe skin diseases
- The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space
- In addition to upfront and technology access payments, etherna is eligible to receive €300 million in development and commercial milestones as well as tiered royalties

The alliance combines and leverages etherna’s innovative proprietary mRNA capabilities and LNP formulations with Almirall’s leading expertise in medical dermatology to accelerate discovery of novel treatment options. Delivery of LNP-formulated mRNA for transient and local translation of therapeutic proteins offers a unique opportunity to encode for multiple therapeutically active components in a single treatment.

Etherna and Almirall will work collaboratively on the research activities, while Almirall will lead clinical development and commercialization. Under the terms of the agreement, etherna will receive upfront and technology access payments. In addition, etherna is eligible to receive success-based development and commercial milestone payments that could exceed €300 million contingent upon launch and commercial success of multiple products, as well as tiered royalties based upon future global sales.

Sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com